Meeting
2014 ASCO Annual Meeting
Molecular testing prior to first-line therapy in patients with stage IV nonsquamous non-small cell lung cancer (NSCLC): A survey of U.S. medical oncologists.
Authors
Mark R. Green
Xcenda, Palm Harbor, FL
Mark R. Green , Joanne Willey , Arden Buettner , Maria Lankford , Doug B. Neely , Suresh S. Ramalingam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8097)
DOI
10.1200/jco.2014.32.15_suppl.8097
Abstract #
8097
Poster Bd #
278
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).
First Author: Sehhoon Park
Poster
2023 ASCO Annual Meeting
Relevance and accuracy of ChatGPT-generated NGS reports with treatment recommendations for oncogene-driven NSCLC.
First Author: Zac Hamilton
Poster
2016 ASCO Annual Meeting
Nomograms to predict the presence of EGFR mutations and ALK rearrangements in non-small-cell lung carcinoma.
First Author: Wenfeng Fang
Poster
2014 ASCO Annual Meeting
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
First Author: David Paul Carbone